Dr Reddy’s Laboratories failed to cheer the market despite June quarter net profit doubling. Analysts see concern over the US business and pressure on operating performance as key drags. These concerns have prompted traders to build bearish bets on the stock. Chandan Taparia, derivative analyst at Motilal Oswal, said the weakness could continue and the stock could drift down to Rs 3,950.
ArisInfra Solutions shares GMP at 11% in unlisted market. Check IPO details
ArisInfra Solutions shares: The Grey Market Premium (GMP) represents the price at which shares of a forthcoming IPO are being traded in the unofficial market